Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 114.60K | 181.30K | 1.70K | -- | 136.50K |
| Gross Profit | -114.60K | -181.30K | -1.70K | -- | -136.50K |
| SG&A Expenses | 245.00K | 315.10K | 296.50K | 778.20K | 317.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 375.70K | 516.00K | 364.40K | 837.50K | 512.00K |
| Operating Income | -375.70K | -516.00K | -364.40K | -837.50K | -512.00K |
| Income Before Tax | -377.40K | -512.60K | -205.40K | -829.50K | -540.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -377.40K | -512.60K | -205.40K | -829.50K | -540.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -377.40K | -512.60K | -205.40K | -829.50K | -540.20K |
| EBIT | -375.70K | -516.00K | -364.40K | -837.50K | -512.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 170.66M | 169.61M | 167.24M | 148.48M | 139.95M |
| Average Diluted Shares Outstanding | 170.66M | 169.61M | 167.24M | 148.48M | 139.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |